

Rec'd PCT/PTC 18 OCT 2005

Docket No.: B45311

DECLARATION

10/517420

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"IMMUNOGENIC COMPOSITIONS"

the specification of which-(check one)

☐ is attached hereto.

☒ was filed on 6 June 2003 as Serial No. PCT/EP03/06096
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
0213365.0	GB	11 June 2002	YES
0300914.9	GB	15 January 2003	YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

BEST AVAILABLE COPY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

100 Full Name of Inventor: Teresa Elisa Virginia CABEZON SILVA

Inventor's Signature: Teresa Silva

Date: 09/12/2004

Residence: RIXENSART, BELGIUM BEX

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

200 Full Name of Inventor: Jonathan H ELLIS


Inventor's Signature: Jonathan Ellis JP

Date: 16/12/04

Residence: STEVENAGE, HERTFORDSHIRE, GB


Citizenship: BRITISH GBX

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939



BEST AVAILABLE COPY

300 Full Name of Inventor: Catherine Marie Ghislaine GERARD

Inventor's Signature: 

Date: 07/12/07

Residence: RIXENSART, BELGIUM

BEX

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

400 Full Name of Inventor: Paul A HAMBLIN

Inventor's Signature: 

Date: 14/12/2004


Residence: STEVENAGE, HERTFORDSHIRE, GB

Citizenship: BRITISH

GIBX

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

500 Full Name of Inventor: Remi M PALMANTIER

Inventor's Signature: 

Date: 06/12/2004

Residence: RIXENSART, BELGIUM

BEX

Citizenship: FRENCH

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939


BEST AVAILABLE COPY

6-00 Full Name of Inventor: Carlota VINALS Y DE BASSOLS

Inventor's Signature: [Signature]

Date: 02.12.04

Residence: RIXENSART, BELGIUM

BEX

Citizenship: BELGIAN

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

BEST AVAILABLE COPY

Rec'd PCT/PTO 18 OCT 2005

10/517420

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: **Glaxo Group Limited**International Application No./Patent No.: PCT/EP03/06096 Filed/Issue Date: 6 June 2003 Entitled: **IMMUNOGENIC COMPOSITIONS**

Glaxo Group Limited., a corporation, states that it is:


1. ☐ the assignee of the entire right, title, and interest; or2. ☒ an assignee of less than the entire right, title and interest.The extent (by percentage) of its ownership interest is 50 % in the patent application/patent identified above by virtue of either;A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:1. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.2. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.3. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature10 DEC 2004
DateMarcus Jonathan William DALTON

Printed or Typed Name

+44 20 8047 4401

Telephone Number

Attorney and Authorised Official on behalf of Glaxo Group Limited.

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

Rec'd PCT/PTO 18 OCT 2005

10/517420

PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	PCT/EP03/06096
	Filing Date	6 June 2003
	First Named Inventor	Teresa Elisa Virginia CABEZON SILVA
	Title	IMMUNOGENIC COMPOSITIONS
	Art Unit	
	Examiner Name	
	Attorney Docket Number	B45311

I hereby appoint:

☒ Practitioners associated with the Customer Numbers. 20462
Or
☐ Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☐ The address associated with the above-mentioned Customer Number:
Or
☒ The address associated with Customer Number 20462
Or
☐ Firm or Individual Name:

Address:	
Address:	
City:	State: Zip:
Country:	
Telephone:	Fax:

I am the:

☐ Applicant/Inventor:
☒ Assignee or record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature: <i>Marcus Jonathan William Dalton</i>	Date: 10 DEC 2004
Name: Marcus Jonathan William DALTON	Telephone: +44 20 8047 4401
Title and Company: Attorney and Authorised Official, Glaxo Group Limited	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

Rec'd PCT/PTO 18 OCT 2005



GlaxoSmithKline

POWER OF ATTORNEYGlaxoSmithKline
Biologicals S.A.Rue de l'Institut, 29
B-1330 Rixensart
BelgiumTel. +32 (0) 2 656 81 11
Fax. +32 (0) 2 656 80 00
www.gsk.com

BY THIS POWER OF ATTORNEY given this 12th day of June 2002, GLAXOSMITHKLINE BIOLOGICALS S.A. (formerly "SMITHKLINE BEECHAM BIOLOGICALS S.A."), a Company duly incorporated in Belgium under registration number 65945 and having its registered office at 89 rue de l'Institut, B-1330 Rixensart, Belgium, appoints M.J.W. Dalton (hereinafter called "the Attorney") to be the true and lawful Agent and Attorney of the Company on behalf of and in the name of the Company or otherwise to do, perform, exercise and execute or concur with any other person or persons in doing, performing, exercising and executing in any country or countries or jurisdiction in any part of the world all or any of the following powers, act, deeds and things, that is to say:

1. To make application or cause application to be made for the grant to the Company and the proper registration in the name of the Company of any letters patent, registered designs or know-how whatever and to take all steps necessary for the same to be prosecuted and maintained.
2. As the act and deed of the Company to sign, seal and deliver and execute all or any assignments or assurances to the Company of any letters patent, registered designs, know-how or any application therefor for the purpose of fully and effectually vesting and transferring the same into the name of the Company insofar as such documents can be executed without the Company's seal being affixed thereto.
3. As the act and deed for the Company to sign, seal, deliver and execute all or any assignments, assurances, licenses and sub-licenses from the Company of or under any letters patent, registered design, know-how or an application therefor for the purpose of fully and effectually vesting, transferring or granting the same into the name of any person or company (whether in the United Kingdom or elsewhere) insofar as such documents can be executed without the Company's Seal being affixed thereto.
4. To sign and execute all documents relating to applications for letters patent, registered designs, know-how or the renewal thereof or to assignments or assurances of the same or applications therefor.
5. To act in regard to all official communications which may now or hereafter to be addressed to the Company or to the Attorney relating to applications for letters patent, registered designs, know-how or the renewal thereof in such manner that the Attorney may be recognized as the authorized Agent of the Company in all proceedings incidental thereto.
6. For, or in connection with any letters patent, registered designs, know-how or application therefor to sign, seal, deliver and execute any Power of Attorney or other deed or document:

G:\SEC\MATPOA\Dalton-Patent-Bio.doc

R. C. Nivelle - 65945
TVA : BE400473918
Date: 18/09/2005 18:33:54


- a) authorizing any firm or patent agents in the United Kingdom of Great Britain and Northern Ireland to act on behalf of the Company;
 - b) authorizing any person, persons, firm or company practising as patent agents or otherwise entitled to act as agents for all matters relating to letters patent, registered designs or know-how outside the United Kingdom of Great Britain and Northern Ireland to act on behalf of the Company, with powers of substitution.
7. To initiate or cause to be initiated or to appear as defendant, complaine, interpleader or enjoined third party in any Patent Office or Registry or Court or other agency or government department or otherwise responsible for the registration or protection of letters patent, registered designs or know-how in respect of any proceedings or application whatsoever relating to such proprietary rights whether in the name of the Company or not and to cause such proceedings or applications to be maintained or withdrawn.

AND THE COMPANY HEREBY RATIFIES AND CONFIRMS and agrees to ratify and confirm all and whatsoever the Attorney or any person, persons, firm or company appointed by him shall lawfully do or have done or cause to be done by virtue to the authority herein contained, including in such ratification and confirmation all and whatsoever the hereby appointed Attorney may already have done in purported exercise of the authorities presently vested in him.

AND THE COMPANY HEREBY DECLARES that this Power of Attorney is in substitution for and shall revoke all previous Powers of Attorney granted by the Company to the Attorney to do any of the acts and things hereby authorized to be done and remaining unrevoked PROVIDED that nothing herein contained shall affect the validity of any act or thing done by the Attorney by virtue thereof before the execution of this Power.

IN WITNESS WHEREOF the Company has caused its Common Seal to be hereunto affixed the day and year first before written.

GLAXOSMITHKLINE BIOLOGICALS S.A.


Jean-Luc Bocken
Director


Jean-Pierre Suin
Director

